RT Journal Article
T1 Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature.
A1 Tena, Isabel
A1 Gupta, Garima
A1 Tajahuerce, Marcos
A1 Benavent, Marta
A1 Cifrián, Manuel
A1 Falcon, Alejandro
A1 Fonfria, María
A1 Del Olmo, Maribel
A1 Reboll, Rosa
A1 Conde, Antonio
A1 Moreno, Francisca
A1 Balaguer, Julia
A1 Cañete, Adela
A1 Palasí, Rosana
A1 Bello, Pilar
A1 Marco, Alfredo
A1 Ponce, José Luis
A1 Merino, Juan Francisco
A1 Llombart, Antonio
A1 Sanchez, Alfredo
A1 Pacak, Karel
K1 Paraganglioma
K1 SDHB
K1 metastatic
K1 metronomic
K1 temozolomide
AB Metastatic pheochromocytoma and paraganglioma (mPHEO/PGL) are frequently associated with succinate dehydrogenase B (SDHB) mutations. Cyclophosphamide-dacarbazine-vincristine (CVD) regimen is recommended as standard chemotherapy for advanced mPHEO/PGL. There is limited evidence to support the role of metronomic schemes (MS) of chemotherapy in mPHEO/PGL treatment. We report 2 patients with SDHB-related mPGL who received a regimen consisting of MS temozolomide (TMZ) and high-dose lanreotide after progression on both CVD chemotherapy and high-dose lanreotide. Molecular profiling of the tumor tissue from both patients revealed hypermethylation of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter. In one patient, progression-free survival was 13 months and the second patient remained under treatment after 27 months of stabilization of metabolic response of his disease. Treatment was well tolerated, and adverse effects were virtually absent. A modification in the scheme of TMZ from standard schemes to MS is safe and feasible and can be considered in patients with progressive mPHEO/PGL refractory to dacarbazine in standard doses.
SN 1179-5549
YR 2018
FD 2018-04-09
LK https://hdl.handle.net/10668/28158
UL https://hdl.handle.net/10668/28158
LA en
DS RISalud
RD Apr 17, 2025